

## Bavarian Nordic upgrades the financial guidance for 2008

Bavarian Nordic raises its expectations for revenue, result before tax and the net free liquidity for the financial year 2008.

The improved revenue is due to higher income than expected from the RFP-1 and RFP-2 contracts. The result before tax is improved as a result of higher revenue, cost savings and timing differences in some clinical studies as well as in production planning.

As a consequence hereof, Bavarian Nordic raises the full year expectations for revenue from approx. DKK 180 million to approx. DKK 210 million. The result before tax is expected to improve from approx. DKK -225 million to DKK -185 million. The company's net free liquidity at year-end is expected to increase from approx. DKK 620 million to approx. DKK 730 million.

Anders Hedegaard, President & CEO of Bavarian Nordic, said: "During 2008 we have significantly strengthened our pipeline and still we are able to improve our result. This is very encouraging and it further strengthens our already strong financial position, especially the net free liquidity, which is important during the current market conditions. Furthermore the strong financial position contributes to obtaining the company's long term strategic objectives."

Asger Aamund  
Chairman

---

### Contact:

Anders Hedegaard, President & CEO | +45 23 20 30 64

#### **Forward-looking statements**

*This announcement includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.*

#### **About Bavarian Nordic**

*Bavarian Nordic A/S is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's business strategy is focused in three areas: biodefence, cancer and infectious diseases. Bavarian Nordic's proprietary and patented technology MVA-BN<sup>®</sup> is one of the world's safest, multivalent vaccine vectors. Bavarian Nordic has ongoing contracts with the US government for the late-stage development and procurement of the company's third-generation smallpox vaccine, IMVAMUNE<sup>®</sup>.*

*Bavarian Nordic is listed on NASDAQ OMX Copenhagen under the symbol BAVA.*

*For more information please visit [www.bavarian-nordic.com](http://www.bavarian-nordic.com)*